U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases announces the availability of funding for implementation of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus: Network Research Sites (UH2/UH3) Phase Innovation Awards Grant. The goal of the program is to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of rheumatoid arthritis, lupus, and related autoimmune diseases. This award supports an initial milestone-driven UH2 (exploratory) funding period, with possible rapid transition to the UH3 (implementation . . .

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

RFP | March 24, 2014

Federal Government Announces Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus: Network Research Sites (UH2/UH3) Phase Innovation Awards Grant Funding

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member